Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial
- PMID: 19493352
- PMCID: PMC2717450
- DOI: 10.1186/cc7903
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial
Abstract
Introduction: The development of resistance by bacterial species is a compelling issue to reconsider indications and administration of antibiotic treatment. Adequate indications and duration of therapy are particularly important for the use of highly potent substances in the intensive care setting. Until recently, no laboratory marker has been available to differentiate bacterial infection from viral or non-infectious inflammatory reaction; however, over the past years, procalcitonin (PCT) is the first among a large array of inflammatory variables that offers this possibility. The present study aimed to investigate the clinical usefulness of PCT for guiding antibiotic therapy in surgical intensive care patients.
Methods: All patients requiring antibiotic therapy based on confirmed or highly suspected bacterial infections and at least two concomitant systemic inflammatory response syndrome criteria were eligible. Patients were randomly assigned to either a PCT-guided (study group) or a standard (control group) antibiotic regimen. Antibiotic therapy in the PCT-guided group was discontinued, if clinical signs and symptoms of infection improved and PCT decreased to <1 ng/ml or the PCT value was >1 ng/ml, but had dropped to 25 to 35% of the initial value over three days. In the control group antibiotic treatment was applied as standard regimen over eight days.
Results: A total of 110 surgical intensive care patients receiving antibiotic therapy after confirmed or high-grade suspected infections were enrolled in this study. In 57 patients antibiotic therapy was guided by daily PCT and clinical assessment and adjusted accordingly. The control group comprised 53 patients with a standardized duration of antibiotic therapy over eight days. Demographic and clinical data were comparable in both groups. However, in the PCT group the duration of antibiotic therapy was significantly shorter than compared to controls (5.9 +/- 1.7 versus 7.9 +/- 0.5 days, P < 0.001) without negative effects on clinical outcome.
Conclusions: Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistance and costs in intensive care medicine. ANNOTATION: Results were previously published in German in Anaesthesist 2008; 57: 571-577 (PMID: 18463831).
Trial registration: ISRCTN10288268.
Figures






Comment in
-
When once is not enough--further evidence of procalcitonin-guided antibiotic stewardship.Crit Care. 2009;13(4):165. doi: 10.1186/cc7935. Epub 2009 Jul 13. Crit Care. 2009. PMID: 19664168 Free PMC article.
-
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: some research questions.Crit Care. 2009;13(4):414; author reply 414. doi: 10.1186/cc7958. Epub 2009 Jul 30. Crit Care. 2009. PMID: 19664199 Free PMC article. No abstract available.
Similar articles
-
Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.Langenbecks Arch Surg. 2009 Mar;394(2):221-6. doi: 10.1007/s00423-008-0432-1. Epub 2008 Nov 26. Langenbecks Arch Surg. 2009. PMID: 19034493 Clinical Trial.
-
Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial.Neonatology. 2010;97(2):165-74. doi: 10.1159/000241296. Epub 2009 Sep 24. Neonatology. 2010. PMID: 19776651 Clinical Trial.
-
[Antibiotic treatment of surgical intensive care patients: procalcitonin to guide duration of therapy].Anaesthesist. 2008 Jun;57(6):571-7. doi: 10.1007/s00101-008-1379-x. Anaesthesist. 2008. PMID: 18463831 Clinical Trial. German.
-
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25. Surg Infect (Larchmt). 2013. PMID: 24274059 Review.
-
Procalcitonin to guide antibiotic therapy in the ICU.Int J Antimicrob Agents. 2015 Dec;46 Suppl 1:S19-24. doi: 10.1016/j.ijantimicag.2015.10.012. Epub 2015 Nov 1. Int J Antimicrob Agents. 2015. PMID: 26607343 Review.
Cited by
-
Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.Chest. 2017 Jan;151(1):23-33. doi: 10.1016/j.chest.2016.06.046. Epub 2016 Aug 25. Chest. 2017. PMID: 27568580 Free PMC article.
-
The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.Support Care Cancer. 2011 Oct;19(10):1593-600. doi: 10.1007/s00520-010-0987-6. Epub 2010 Aug 28. Support Care Cancer. 2011. PMID: 20803037 Free PMC article.
-
Introduction of Procalcitonin Testing and Antibiotic Utilization for Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Infect Dis (Auckl). 2019 Jun 12;12:1178633719852626. doi: 10.1177/1178633719852626. eCollection 2019. Infect Dis (Auckl). 2019. PMID: 31223234 Free PMC article.
-
Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Curr Oncol Rep. 2017 Mar;19(3):20. doi: 10.1007/s11912-017-0578-5. Curr Oncol Rep. 2017. PMID: 28271398 Review.
-
Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.Intensive Care Med. 2015 Oct;41(10):1739-51. doi: 10.1007/s00134-015-3978-8. Epub 2015 Jul 21. Intensive Care Med. 2015. PMID: 26194026 Review.
References
-
- Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596. doi: 10.1097/01.CCM.0000217961.75225.E9. - DOI - PubMed
-
- ACCP/SCCM Consensus Conference Committee Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous